Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind placebo-controlled study of HRS-1780 in uncontrolled or resistant hypertension
CTR20262726Phase 3Active
- Sponsor
- Shandong Sende
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-1780 in hypertension (HTN), resistant hypertension (RH), sponsored by Shandong Sende. Started Jul 2026; status: active.
02
Drugs
HRS-1780
03
Conditions
hypertension (HTN)resistant hypertension (RH)
Beyond the preview
Go deeper on CTR20262726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262726.